Streptokinase: Biochemistry and Phamacokinetics

  • H. Joost Kruik
  • Willemien J. Kollöffel
  • Freek W. A. Verheugt
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


Streptokinase, one of the first thrombolytic agents to be discovered, has now been used in many hundreds of thousands of patients with acute myocardial infarction. The drug was first discovered in 1933 by William Tillet, who called it fibrolysin [1], but only in 1947 were the first tests done on humans to lyse chronic thoracic empyemas, with considerable success. The intravenous administration of streptokinase was delayed because of difficulties in purifying the protein. In the 1960s, Behringwerke AG and Kabi Pharmacia made the drug available for widespread therapeutic use. The first trials using streptokinase in patients with acute myocardial infarction, published between 1978 and 1988, showed a significant survival benefit compared with conservative treatment or placebo [2, 3, 4].


Acute Myocardial Infarction Fibrinolytic Activity Thrombolytic Agent Intravenous Streptokinase Suspected Acute Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tillett WS, Garner RL. The fibrinolytic activity of streptococci. J Exp Med 58:485, 1933.CrossRefPubMedGoogle Scholar
  2. 2.
    European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med 301:797, 1979.CrossRefGoogle Scholar
  3. 3.
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397, 1986.PubMedGoogle Scholar
  4. 4.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349, 1988.Google Scholar
  5. 5.
    Grierson DS, Bjornsson TD. Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity. Clin Pharmacol Ther 41:304, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    Peuhkurinen KJ, Risteli L, Melkko JT, Linnaluoto M, Jounela A, Risteli J. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 83:1969, 1991.PubMedGoogle Scholar
  7. 7.
    Goa KL, Henwood JM, Stolz JF, Langley MS, Clissold SP. Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction. Drugs 39:693, 1990.PubMedCrossRefGoogle Scholar
  8. 8.
    Oliven A, Gidron E. Orally and rectally administered streptokinase. Investigation of its absorption and activity. Pharmacology 22:135, 1981.PubMedGoogle Scholar
  9. 9.
    Gemmill JD, Hogg KJ, Burns JMA, Rae AP, Dunn FG, Fears R, et al. A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. Br J Clin Pharmacol 31:143, 1991.PubMedGoogle Scholar
  10. 10.
    Fletcher AP, Alkjaersig N, Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J Clin Invest 37:1306, 1958.PubMedGoogle Scholar
  11. 11.
    Verstraete M, Vermylen J, Amery A, Vermylen C. Thrombolytic therapy with streptokinase using a standard dosage scheme. Br Med J 5485:454, 1966.CrossRefGoogle Scholar
  12. 12.
    Six AJ, Louwerenburg HW, Braams R, Mechelse K, Mosterd WL, Bredero AC, et al. A double-blind randomized trial of intravenous streptokinase in acute myocardial infarction. Am J Cardiol 65:119, 1990.PubMedCrossRefGoogle Scholar
  13. 13.
    The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity and infarct size at 21 days. N Engl J Med 314:1465, 1986.CrossRefGoogle Scholar
  14. 14.
    The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615, 1993.CrossRefGoogle Scholar
  15. 15.
    Rogers WJ, Mantle JA, Hood WP Jr, Baxley WA, Whitlow PL, Reeves RC, et al. Prospective randomized trial of intravenous and incracoronary streptokinase in acute myocardial infarction. Circulation 68:1051, 1983.PubMedGoogle Scholar
  16. 16.
    McGrath KG, Zeffren B, Alexander J, Kaplan K, Patterson R. Allergic reactions to streptokinase consistent with anaphylactic or antigen antibody complex mediated damage. J Allergy Clin Immunol 76:453, 1984.CrossRefGoogle Scholar
  17. 17.
    Payne ST, Hosker HSR, Allen MB, Bradbury H, Page RL. Transient impairment of renal function after streptokinase treatment. Lancet 2:1398, 1989.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee HS, Cross S, Davidson R, Reid T, Jennings K. Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase. Eur Heart J 14:84, 1993.PubMedGoogle Scholar
  19. 19.
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico. GISSI-2: Randomised trial of intravenous alteplase versus intravenous streptokinase in acute myocardial infarction. Lancet 336: 65, 1990.Google Scholar
  20. 21.
    Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mottensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials. Br Med J 313:652, 1996.Google Scholar
  21. 22.
    Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI)9A trial. Circulation 90: 1624, 1994.PubMedGoogle Scholar
  22. 23.
    The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775, 1996.CrossRefGoogle Scholar
  23. 24.
    Andreotti F, The TIMI 9B and GUSTO IIb trials and the “thrombin hypothesis.” J Thromb Thrombolys 1997, in press.Google Scholar
  24. 25.
    Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, et al. One-year results form the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 94:1233, 1996.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • H. Joost Kruik
  • Willemien J. Kollöffel
  • Freek W. A. Verheugt

There are no affiliations available

Personalised recommendations